Congenica

Congenica is a digital health company that specializes in providing software and solutions for the analysis and interpretation of genomic data at scale. The company's mission is to drive Precision Medicine and reduce the burden on healthcare systems by delivering automated analysis, diagnosis, and treatment solutions to healthcare providers and patients worldwide. One of Congenica's notable achievements is receiving the CE Mark under the In Vitro Diagnostics Directive for both rare diseases and somatic and inherited cancer, making its platform the only product of its kind with this distinction. This recognition uniquely positions Congenica to drive the ubiquitous use of complex data in routine clinical care. The company's products and services are consolidated on a single scalable, automated analysis, and diagnostic platform that encompasses inherited disease, somatic cancer, pharma insights, and pathogen surveillance. Founded in 2014 based on work at the Wellcome Trust Sanger Institute and the UK NHS, Congenica has established itself as the exclusive clinical decision support partner for the NHS Genomic Medicine Service. Moreover, it has a global footprint supporting leading international laboratories, academic medical centers, hospitals, and biopharmaceutical companies. The headquarters of Congenica is located in the United Kingdom. In March 2021, Congenica secured a Series C investment, with QVentures participating as the lead investor. This investment underlines the confidence of the investor community in Congenica's innovative approach and the potential of its platform to make a significant impact in the healthcare and biotechnology industries.